Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX) released its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10), Zacks reports. The business had revenue of $72.79 million during the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.The company’s quarterly revenue was up 91.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.83) EPS.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Commercial revenue grew strongly: Revuforj and Niktimvo generated combined second-quarter revenue of $115 million. Revuforj revenue rose 91% year over year to $54.7 million, while Niktimvo collaboration revenue increased 67% to $18.1 million.
• Revuforj treatment duration is extending, particularly among patients resuming therapy after stem-cell transplant and those who do not undergo transplant. However, new patient starts declined sequentially in the quarter, which management attributed to normal variability, competition, clinical-trial enrollment and patient availability.
• Niktimvo continues to expand in chronic GVHD: The drug captured approximately one-third of the third-line-plus market within 18 months of launch, with 60%–70% of patients remaining on treatment for at least 12 months. Phase II readouts in idiopathic pulmonary fibrosis and frontline chronic GVHD are expected in the fourth quarter and could open larger markets.
• The pipeline has several near-term catalysts. Syndax expects additional frontline AML and post-transplant Revuforj data, NUP98 leukemia data and progress toward pivotal trials; it also plans an IND for its CNS-penetrant EGFR inhibitor by year-end 2026 and a 2027 Phase I start for its next-generation menin inhibitor in myelofibrosis.
• Financial flexibility remains strong: Syndax ended the quarter with $575 million in cash and investments, including net proceeds from a $250 million convertible-notes offering. Management maintained its 2026 R&D and SG&A expense guidance of approximately $400 million and said the company is funded through profitability.

Syndax Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:SNDX traded up $0.52 during midday trading on Wednesday, reaching $19.60. The company’s stock had a trading volume of 1,306,245 shares, compared to its average volume of 1,613,214. The company has a quick ratio of 5.06, a current ratio of 5.47 and a debt-to-equity ratio of 8.26. The firm has a 50 day moving average of $20.40 and a 200-day moving average of $21.38. The firm has a market capitalization of $1.74 billion, a P/E ratio of -7.03 and a beta of 0.40. Syndax Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $25.59.

Insider Transactions at Syndax Pharmaceuticals

In related news, CMO Nicholas A.J. Botwood sold 34,280 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.00, for a total transaction of $617,040.00. Following the sale, the chief marketing officer owned 60,885 shares of the company’s stock, valued at $1,095,930. The trade was a 36.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael A. Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total transaction of $784,770.00. Following the transaction, the chief executive officer owned 484,843 shares of the company’s stock, valued at $11,752,594.32. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 105,914 shares of company stock valued at $2,120,789. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently modified their holdings of SNDX. Larson Financial Group LLC raised its position in shares of Syndax Pharmaceuticals by 192.2% in the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after purchasing an additional 1,922 shares during the last quarter. Quantbot Technologies LP bought a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at about $53,000. Smartleaf Asset Management LLC increased its stake in Syndax Pharmaceuticals by 2,698.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock valued at $55,000 after purchasing an additional 2,564 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Syndax Pharmaceuticals in the second quarter worth about $66,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock worth $79,000 after buying an additional 4,308 shares in the last quarter.

Syndax Pharmaceuticals News Summary

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 92% year over year to approximately $73 million. Revuforj (revumenib) generated $54.7 million in net revenue, up 91%, while Niktimvo (axatilimab-csfr) produced $60.3 million in net revenue and $18.1 million in collaboration revenue. Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Syndax expanded its development pipeline with a mutant-selective allosteric EGFR inhibitor for non-small cell lung cancer and a next-generation menin inhibitor for myelofibrosis. The company also expects topline Phase 2 data in the fourth quarter of 2026 for axatilimab in idiopathic pulmonary fibrosis and frontline chronic graft-versus-host disease. Syndax Business Update
• Positive Sentiment: HC Wainwright maintained a Buy rating, indicating continued confidence in Syndax’s outlook, although it lowered its price target from $40 to $38. Benzinga analyst update
• Neutral Sentiment: Management discussed the second-quarter results and business outlook during its earnings call, providing additional context on the commercial portfolio and pipeline programs. Syndax Q2 2026 Earnings Call Transcript
• Negative Sentiment: Syndax reported a second-quarter loss of $0.55 per share, wider than the analyst consensus loss of $0.45, while revenue of $72.79 million fell short of the $79.36 million estimate. The loss nevertheless improved from $0.83 per share in the year-earlier quarter. Syndax Q2 Earnings Report

Wall Street Analysts Forecast Growth

SNDX has been the subject of a number of recent analyst reports. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday. HC Wainwright decreased their price objective on shares of Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a report on Wednesday. Barclays raised their target price on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Friday, June 12th. Finally, Weiss Ratings lowered shares of Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $42.36.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.